FindTrial
Sign In

MEDI-507

DRUG11 trials

Sponsors

MedImmune LLC, Massachusetts General Hospital, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

CancerEnd Stage Renal DiseaseGraft Versus Host DiseaseGraft-Versus-Host DiseaseKidney DiseasesKidney Failure, ChronicKidney TransplantationLeukemia

Phase 1

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
TerminatedNCT00105313
MedImmune LLCCancer, Leukemia, Lymphoma
Start: 2005-02-28Target: 80Updated: 2007-06-14
Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease
TerminatedNCT00123942
MedImmune LLCLymphoproliferative Disorders
Start: 2004-04-30Target: 31Updated: 2007-06-14
Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)
CompletedNCT00806208
MedImmune LLCGraft-Versus-Host Disease
Start: 1999-01-31End: 2000-03-31Updated: 2008-12-11
Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease
CompletedNCT00806728
MedImmune LLCCancer, Graft-Versus-Host Disease
Start: 1998-05-31End: 1998-12-31Updated: 2008-12-11
A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection
CompletedNCT00807794
MedImmune LLCKidney Diseases
Start: 1997-02-28End: 1998-01-31Updated: 2008-12-12
Study of MEDI 507 in the Treatment of Pediatric Patients
CompletedNCT00813618
MedImmune LLCGraft Versus Host Disease
Start: 1999-09-30End: 2004-08-31Updated: 2008-12-23
Renal Allograft Tolerance Through Mixed Chimerism
CompletedNCT01780454
Massachusetts General HospitalEnd Stage Renal Disease
Start: 2013-03-31End: 2020-06-30Updated: 2021-04-19

Phase 2

Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
TerminatedNCT00113646
Massachusetts General HospitalLeukemia, Lymphoma, Multiple Myeloma +1
Start: 2002-11-30End: 2007-12-31Updated: 2018-03-16
Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis
CompletedNCT00192452
MedImmune LLCPsoriasis
Start: 2001-03-31End: 2001-12-31Target: 120Updated: 2006-10-25
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
CompletedNCT00540618
MedImmune LLCPlaque Psoriasis
Start: 2001-09-30End: 2003-07-31Updated: 2007-11-28
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
CompletedNCT00801632
National Institute of Allergy and Infectious Diseases (NIAID)Kidney Failure, Chronic, Kidney Transplantation
Start: 2008-12-31End: 2014-11-30Updated: 2015-11-10

Related Papers

KLRG1 re-defines a leukemic clone of CD8 effector T cells sensitive to PI3K inhibitor in T cell large granular lymphocytic leukemia
Cell Reports Medicine2025-03-272 citations
Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell Leukemias
HemaSphere2021-06-015 citations